ClinicalTrials.gg
RecruitingNCT07043543BLADAPTUpdated Nov 9, 2026

Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

An interventional study of Adaptive radiotherapy and standard radiotherapy in Bladder Cancer, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 161 studies in Urinary Bladder Neoplasms with a site in France — 41 open to participants now, 63 under way, 16 of them phase 3. Urinary Bladder Neoplasms · France.

Planned enrollment
79th of 130
120 · median 169
Started
2026
with 8 others
No phase
17 of 161
7 open now
Primary completion
2029-01
later than 44 of 62 live
Registered
146th of 161
by date

Among the 161 studies in Urinary Bladder Neoplasms with a site in France, this one is the 79th largest by planned enrollment of the 130 interventional ones that give a count, is one of 9 that started in 2026, is one of 17 with no phase, reaches primary completion later than 44 of the 62 other live ones, and was the 146th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

41 of the 161 studies in Urinary Bladder Neoplasms with a site in France are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Urinary Bladder Neoplasms with a site in France, or all of them as a file.
02

Study summary

Trimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or refuse surgery. One of the main challenges of TMT is the planning and delivery of radiation therapy. Indeed, the bladder is a mobile hollow organ subject to repletion, with variations in size and shape during and between radiotherapy sessions. Standard radiotherapy techniques require large planning target volume margins around the bladder, which can be responsible for irradiation of a large volume of large and small bowel with grade 2 and 3 toxicities.

Adaptive radiotherapy allows for the generation of a treatment fraction personalized to a patient's anatomical modification with margin reduction and improves the dosimetric quality of the delivered plans.

The hypothesis is that this improvement results in radiation-induced toxicity improvement.

Read the detailed description

In 2023, the incidence of muscle-infiltrating bladder cancer (MIBC) in France was 14062 cases, 81% of which were in men.

The standard treatment for MIBC is cystectomy preceded by neoadjuvant chemotherapy. Trimodal therapy (TMT), consisting of transurethral resection of bladder tumors (TURBT) followed by radiotherapy (RT) and chemotherapy (CT), has emerged as a valuable therapeutic de-escalation alternative in patients who are inoperable or refuse surgery with its physical and psychological sequelae. TMT provides survival outcomes identical to cystectomy in selected patients and allows for bladder preservation in successful cases. TMT is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder who failed intravesical therapy.

One of the main challenges of TMT is the planning and delivery of radiation therapy. Indeed, the bladder is a mobile hollow organ subject to repletion, with variations in size and shape during radiotherapy sessions (intra-fractional movement) and between sessions (inter-fractional movement). To take into account these movements, standard radiotherapy techniques require large planning target volume (PTV) margins around the bladder, which can be responsible for irradiation of a large volume of large and small bowel with grade 2 and 3 toxicities up to 42% and 17% respectively.

Adaptive radiotherapy (ART) allows for the generation of a treatment fraction personalized to a patient's anatomical modification. While it was until recently only performed "offline", i.e. between two radiotherapy sessions, it is now possible to perform a daily customization of the radiotherapy session ("online") for a given patient to ensure optimal coverage of the target with minimized margins. ART allows PTV margins reduction for MIBC and improves therefore the dosimetric quality of the delivered plans.

The hypothesis is that the dosimetric improvement induced by ART results in radiation-induced toxicity improvement.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Adaptive radiotherapy
  • standard radiotherapy
  • Tri-Modal therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven muscle-infiltrating bladder cancer (de novo MIBC or after a history of non-muscle-invasive bladder cancer) or patients with initial high-grade T1 tumor showing Ta or T1 recurrence, or those with high-grade T1 after a course of intravesical biological therapy or chemotherapy;
  • Age ≥ 18 years;
  • Urothelial carcinoma (transitional cell carcinoma of the bladder, micropapillary, microcystic with trophoblastic differenciation) and squamous cell histological types are allowed;
  • Stage T1-T4aN0M0
  • TransUrethral Resection of Bladder Tumor (TURBT) and Position Emission Tomography- scanner and X-ray Computed Tomography (PET-CT) or Computed Tomography scan of thorax/abdomen/pelvis (without carcinological anomaly) within 8 weeks prior to the start of radiation therapy (if TURBT was performed more than 6 weeks before the inclusion visit, a new TURBT or, at least, a cystoscopy showing no progression, no residual tumour or regrowth must be done);
  • Suitable for radiotherapy;
  • /World Human Organisation (ECOG/WHO) performance status from 0 to 2
  • Negative pregnancy test (blood or urine), for women of childbearing age only;
  • If the patient is sexually active, he/she must agree to use deemed adequate and appropriate by the investigator throughout the period of study drug administration and 6 months after the end of treatment for both men and women.
  • Affiliation to the French Social Security System;
  • Dated, written and signed

Exclusion criteria

Exclusion Criteria:

  • Prior pelvic radiation therapy;
  • Patients with previous or concomitant other within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years;
  • Presence of endopenic stent;
  • Inability to comply with the protocol;
  • Grade 1 or greater baseline diarrhea;
  • Uncontrolled inflammatory bowel disease (ulcerative colitis or Crohn's disease);
  • Uncontrolled immune or cardiac or pulmonary disease;
  • Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons;
  • Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the or to terminate the study;
  • Pregnant or breast-feeding subjects
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    experimental arm

    Adaptive radiotherapy +/- chemotherapy

    Radiation: Adaptive radiotherapy

  • Active comparator
    standard arm

    Standard radiotherapy +/- chemotherapy

    Radiation: standard radiotherapy

Interventions

  • RadiationAdaptive radiotherapy

    Patient will be treated by concomitant: * adaptive radiotherapy 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB). * chemotherapy if not contraindicated : * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or * Gemcitabine: 80 to 100 mg/m2/week Or * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)

  • Radiationstandard radiotherapy

    Patient will be treated by concomitant: * standard 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB). * chemotherapy if not contraindicated : * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or * Gemcitabine: 80 to 100 mg/m2/week Or * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)

06

What researchers measure

Primary outcomes

  1. evaluation of the technique of adaptive radiotherapy in terms of acute Gastro-Intestinal toxicity.

    rate of patients without acute diarrhea grade ≥2

    Time frame: from the Day 1 Radiotherapy to 3 months after the last day of Radiotherapy

Secondary outcomes

  1. Evaluation of all acute toxicities

    description of all acute toxicities according to Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)

    Time frame: from the Day 1 Radiotherapy to 3 months after the last day of Radiotherapy

  2. Evaluation of all late toxicities

    description of all late toxicities according to Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)

    Time frame: from 3 months after the last day of Radiotherapy to 5 years after the last day of Radiotherapy

  3. evaluation of quality of life specific to the cancer disease

    Quality of life will be evaluated using European Organisation for Research and Treatment of Cancer - Quality Life Questionnaire (EORTC QLQ-C30)

    Time frame: at baseline, the last day of radiotherapy, every 3 months after the last day of radiotherapy, during first year and every 6 months then after until 3 years.

  4. evaluation of quality of life and of the measurements specific to the treatment of bladder cancer with muscle invasion

    Quality of life will be evaluated using European Organisation for Research and Treatment of Cancer - Quality Life Questionnaire - Bladder Cancer (EORTC QLQ-BLM30)

    Time frame: at baseline, the last day of radiotherapy, every 3 months after the last day of radiotherapy, during first year and every 6 months then after until 3 years.

  5. evaluation of quality of life for patient ≥ 70 years old in order to establish a minimum standardized geriatric assessment

    Quality of life will be evaluated using Geriatric COre DatasEt oncogeriatric (GCODE) for patient ≥ 70 years old

    Time frame: at baseline, the last day of radiotherapy, every 3 months after the last day of radiotherapy, during first year and every 6 months then after until 3 years.

  6. evaluation of quality of life for patient ≥ 70 years old (Specific to elderly people with cancer)

    Quality of life will be evaluated using European Organisation for Research and Treatment of Cancer - Quality Life Questionnaire-Elderly (EORTC QLQ- ELD30) for patient ≥ 70 years old

    Time frame: at baseline, the last day of radiotherapy, every 3 months after the last day of radiotherapy, during first year and every 6 months then after until 3 years.

  7. assessment of disease free survival

    time interval from randomization to first carcinologic event as local or distant relapse or death

    Time frame: At 3 and 5 years after the last day of Radiotherapy

  8. assessment of cystectomy free survival

    the time interval from randomization to cystectomy

    Time frame: At 3 and 5 years after the last day of Radiotherapy

  9. assessment of overall survival

    the time interval from randomization to death from any cause

    Time frame: At 3 and 5 years after the last day of Radiotherapy

  10. assessment of local control rate

    The presence of non-muscle-invasive or muscle-invasive bladder cancers evaluate by cystoscopy

    Time frame: At 3 and 5 years after the last day of Radiotherapy

  11. assessment of the dosimetric results

    Dosimetric results in terms of treatment volume coverage and Organ At Risk protection

    Time frame: during tthe radiotherapy for both arms

  12. evaluation of the impact of the adaptive process on fractions execution

    Evaluation of duration of the treatment fractions (in minutes) in the two arms. Evaluation of the percentage of fractions fully delivered and the duration of physician/physicist mobilization for the adaptive process

    Time frame: during tthe radiotherapy for both arms

07

Study locations

7 of 11 sites recruiting
08

References and documents

Publications

  • Cabaille M, Khalifa J, Tessier AM, Belhomme S, Crehange G, Sargos P. [A review of adaptive radiotherapy for bladder cancer]. Cancer Radiother. 2021 May;25(3):271-278. doi: 10.1016/j.canrad.2020.08.046. Epub 2021 Jan 2. French. PubMed 33402293 ↗
  • Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kubler H, Stenzl A, Gakis G. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018 Feb;36(2):43-53. doi: 10.1016/j.urolonc.2017.10.002. Epub 2017 Nov 6. PubMed 29102254 ↗
  • Huddart R, Hafeez S, Omar A, Alonzi R, Birtle A, Cheung KC, Choudhury A, Foroudi F, Gribble H, Henry A, Hilman S, Hindson B, Lewis R, Muthukumar D, McLaren DB, McNair H, Nikapota A, Olorunfemi A, Parikh O, Philipps L, Rimmer Y, Syndikus I, Tolentino A, Varughese M, Vassallo-Bonner C, Webster A, Griffin C, Hall E. Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clin Oncol (R Coll Radiol). 2023 Sep;35(9):586-597. doi: 10.1016/j.clon.2023.05.002. Epub 2023 May 9. PubMed 37225552 ↗
  • Hafeez S, Lewis R, Hall E, Huddart R; RAIDER Trial Management Group. Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER). Clin Oncol (R Coll Radiol). 2021 Jun;33(6):e251-e256. doi: 10.1016/j.clon.2021.02.012. Epub 2021 Mar 23. No abstract available. PubMed 33766502 ↗
  • Kool R, Dragomir A, Kulkarni GS, Marcq G, Breau RH, Kim M, Busca I, Abdi H, Dawidek M, Uy M, Fervaha G, Cury FL, Alimohamed N, Izawa J, Jeldres C, Rendon R, Shayegan B, Siemens R, Black PC, Kassouf W. Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis. Eur Urol Oncol. 2024 Dec;7(6):1350-1357. doi: 10.1016/j.euo.2024.01.014. Epub 2024 Feb 6. PubMed 38326142 ↗
  • Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, Jani AB, Cury FL, Hudes RS, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Sandler HM, Feng FY, Efstathiou JA. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec;42(34):4095-4102. doi: 10.1200/JCO.23.02510. Epub 2024 Sep 3. PubMed 39226514 ↗
  • de Haar-Holleman A, van Hoogstraten LMC, Hulshof MCCM, Tascilar M, Bruck K; BlaZIB study group; Meijer RP, Alfred Witjes J, Kiemeney LA, Aben KKH. Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study. Radiother Oncol. 2023 Jun;183:109584. doi: 10.1016/j.radonc.2023.109584. Epub 2023 Mar 1. PubMed 36863459 ↗
  • Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Sreenivasan T, Wallace J, Syndikus I, Sheehan D, Lydon A, Huddart R, James N; BC2001 Investigators. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. Eur Urol. 2022 Sep;82(3):273-279. doi: 10.1016/j.eururo.2022.04.017. Epub 2022 May 14. PubMed 35577644 ↗
  • Sibolt P, Andersson LM, Calmels L, Sjostrom D, Bjelkengren U, Geertsen P, Behrens CF. Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region. Phys Imaging Radiat Oncol. 2020 Dec 18;17:1-7. doi: 10.1016/j.phro.2020.12.004. eCollection 2021 Jan. PubMed 33898770 ↗
  • Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M, Jones J, Balcerzak SP, Crawford ED, Grossman HB. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol. 2001 Jan;165(1):56-60; discussion 60-1. doi: 10.1097/00005392-200101000-00014. PubMed 11125363 ↗
  • Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):853-9. doi: 10.1016/j.ijrobp.2013.11.016. Epub 2013 Dec 21. PubMed 24368064 ↗
  • Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, Colardelle F, Brunel P, Baillet F. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993 Nov;11(11):2150-7. doi: 10.1200/JCO.1993.11.11.2150. PubMed 8229129 ↗
  • Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):511-7. doi: 10.1016/j.ijrobp.2008.08.021. Epub 2008 Oct 30. PubMed 18977098 ↗
  • Kent E, Sandler H, Montie J, Lee C, Herman J, Esper P, Fardig J, Smith DC. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol. 2004 Jul 1;22(13):2540-5. doi: 10.1200/JCO.2004.10.070. PubMed 15226322 ↗
  • Caffo O, Thompson C, De Santis M, Kragelj B, Hamstra DA, Azria D, Fellin G, Pappagallo GL, Galligioni E, Choudhury A. Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials. Radiother Oncol. 2016 Nov;121(2):193-198. doi: 10.1016/j.radonc.2016.09.006. Epub 2016 Oct 5. PubMed 27720221 ↗
  • Bruck K, Meijer RP, Boormans JL, Kiemeney LA, Witjes JA, van Hoogstraten LMC, van der Heijden MS, Donders AR, Franckena M, Uyl de Groot CA, Leliveld AM, Aben KKH, Hulshof MCCM. Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys. 2024 Jan 1;118(1):41-49. doi: 10.1016/j.ijrobp.2023.07.027. Epub 2023 Jul 28. PubMed 37517601 ↗
  • Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. PubMed 35254888 ↗
  • Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, Hernandez V, Linares Espinos E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimae E, Ribal MJ, van der Heijden AG. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29. PubMed 32360052 ↗
  • Willigenburg T, de Muinck Keizer DM, Peters M, Claes A, Lagendijk JJW, de Boer HCJ, van der Voort van Zyp JRN. Evaluation of daily online contour adaptation by radiation therapists for prostate cancer treatment on an MRI-guided linear accelerator. Clin Transl Radiat Oncol. 2021 Jan 14;27:50-56. doi: 10.1016/j.ctro.2021.01.002. eCollection 2021 Mar. PubMed 33532630 ↗
  • Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E. Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies. Cancer. 2011 Mar 15;117(6):1190-6. doi: 10.1002/cncr.25667. Epub 2010 Oct 19. PubMed 20960501 ↗
  • Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, Pater J, Sullivan LD. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996 Nov;14(11):2901-7. doi: 10.1200/JCO.1996.14.11.2901. PubMed 8918486 ↗
  • Gronborg C, Vestergaard A, Hoyer M, Sohn M, Pedersen EM, Petersen JB, Agerbaek M, Muren LP. Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. Acta Oncol. 2015;54(9):1461-6. doi: 10.3109/0284186X.2015.1062138. Epub 2015 Aug 27. PubMed 26313410 ↗
  • Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9. PubMed 28081860 ↗
  • Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3. PubMed 25366678 ↗
  • Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6. doi: 10.1016/j.eururo.2005.04.006. Epub 2005 Apr 21. PubMed 15939524 ↗
  • Shi H, Zhang W, Bi X, Wang D, Xiao Z, Guan Y, Guan K, Tian J, Bai H, Hu L, Cao C, Jiang W, Hu Z, Zhang J, Chen Y, Zheng S, Feng X, Li C, Li Y, Ma J, Liu Y, Zhou A, Shou J. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Cancer Res Treat. 2021 Oct;53(4):1156-1165. doi: 10.4143/crt.2020.1356. Epub 2021 Feb 10. PubMed 33592141 ↗
  • Cho SW, Lim SH, Kwon GY, Kim CK, Park W, Pyo H, Chung JH, Song W, Sung HH, Jeong BC, Park SH. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies. Cancer Res Treat. 2024 Jul;56(3):893-897. doi: 10.4143/crt.2024.015. Epub 2024 Feb 15. PubMed 38374699 ↗
  • Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996 Jan;14(1):119-26. doi: 10.1200/JCO.1996.14.1.119. PubMed 8558186 ↗
  • Astrom LM, Behrens CP, Calmels L, Sjostrom D, Geertsen P, Mouritsen LS, Serup-Hansen E, Lindberg H, Sibolt P. Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits. Radiother Oncol. 2022 Jun;171:37-42. doi: 10.1016/j.radonc.2022.03.014. Epub 2022 Mar 28. PubMed 35358605 ↗
  • Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, Clarke NW, Cowan RA. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):420-5. doi: 10.1016/j.ijrobp.2004.05.074. PubMed 15667962 ↗
  • Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1310-6. doi: 10.1016/s0360-3016(03)00763-6. PubMed 14630267 ↗
  • Borut K, Lijana ZK. Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer. Radiother Oncol. 2012 Mar;102(3):412-5. doi: 10.1016/j.radonc.2011.07.026. Epub 2011 Sep 2. PubMed 21890225 ↗
  • Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011 Feb 20;29(6):733-8. doi: 10.1200/JCO.2010.31.5721. Epub 2011 Jan 4. PubMed 21205754 ↗
  • Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998 Nov;16(11):3576-83. doi: 10.1200/JCO.1998.16.11.3576. PubMed 9817278 ↗
  • McNair HA, Joyce E, O'Gara G, Jackson M, Peet B, Huddart RA, Wiseman T. Radiographer-led online image guided adaptive radiotherapy: A qualitative investigation of the therapeutic radiographer role. Radiography (Lond). 2021 Nov;27(4):1085-1093. doi: 10.1016/j.radi.2021.04.012. Epub 2021 May 15. PubMed 34006442 ↗
  • James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012 Apr 19;366(16):1477-88. doi: 10.1056/NEJMoa1106106. PubMed 22512481 ↗
  • Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, Crundwell M, Adab FA, Sheehan D, Syndikus I, Hendron C, Lewis R, Waters R, James ND. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):261-9. doi: 10.1016/j.ijrobp.2013.06.2044. PubMed 23958147 ↗
  • Khalifa J, Supiot S, Pignot G, Hennequin C, Blanchard P, Pasquier D, Magne N, de Crevoisier R, Graff-Cailleaud P, Riou O, Cabaille M, Azria D, Latorzeff I, Crehange G, Chapet O, Roupret M, Belhomme S, Mejean A, Culine S, Sargos P. Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiother Oncol. 2021 Aug;161:95-114. doi: 10.1016/j.radonc.2021.06.011. Epub 2021 Jun 10. PubMed 34118357 ↗
  • Amestoy F, Roubaud G, Antoine M, Fonteyne V, Baumann BC, Christodouleas J, Roupret M, Azria D, Zilli T, Hennequin C, Xylinas E, Sargos P; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Crit Rev Oncol Hematol. 2019 Oct;142:76-85. doi: 10.1016/j.critrevonc.2019.06.010. Epub 2019 Jul 16. PubMed 31377435 ↗
  • Fabiano E, Riou O, Pointreau Y, Perichon N, Durdux C. Role of radiotherapy in the management of bladder cancer: Recommendations of the French society for radiation oncology. Cancer Radiother. 2022 Feb-Apr;26(1-2):315-322. doi: 10.1016/j.canrad.2021.11.006. Epub 2021 Dec 23. PubMed 34955411 ↗
  • Reignier PL, Gauthier H, Hennequin C, Aussedat Q, Xylinas E, Desgrandchamps F, Culine S, Masson-Lecomte A, Dumont C. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer. World J Urol. 2023 Nov;41(11):3249-3255. doi: 10.1007/s00345-023-04506-9. Epub 2023 Jul 6. PubMed 37410102 ↗
  • Thompson C, Joseph N, Sanderson B, Logue J, Wylie J, Elliott T, Lyons J, Anandadas C, Choudhury A. Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):732-739. doi: 10.1016/j.ijrobp.2016.11.040. Epub 2016 Nov 27. PubMed 28244408 ↗

Individual participant data

Plan to share: Yes — Following publication of study results in a peer-reviewed journal, all data and study documentation, including anonymised participant-level data, the study protocol, the statistical analysis plan, and the clinical study report, will be made available upon execution of a data-sharing agreement between the sponsor and the requester.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jan 2029, 34 months after the start.

Of 237 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 69. This study's planned 34 months is below that.

Counting every sponsor, half of 246 studies reached it within 38 months; a quarter within 18 and three quarters within 69.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 29, 2025
StartActual
Mar 4, 2026was Jan 2026
Primary completionEst.
Jan 30, 2029
CompletionEst.
Sep 30, 2033
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
2 sites added, 2 sites removed. 9 sites changed recruiting status (6 now recruiting, 3 now not yet recruiting)
Show 9 sites
  • Institut du Cancer de Montpellier · Montpellier, Franceno status→Recruiting
  • Institut de Cancérologie de l'Ouest · Saint-Herblain, Franceno status→Not yet recruiting
  • Centre Oscar Lambret · Lille, Franceno status→Recruiting
  • Centre de radiothérapie Bayard · Villeurbanne, Franceno status→Not yet recruiting
  • Centre Henri Becquerel · Rouen, Franceno status→Recruiting
  • Institut Sainte Catherine · Avignon, Franceno status→Recruiting
  • Centre de radiothérapie Saint-Louis · Toulon, Franceno status→Recruiting
  • Hôpital Tenon · Paris, Franceno status→Recruiting
  • Institut Curie · Saint-Cloud, Franceno status→Not yet recruiting
Show 2 added (2 France)
  • Centre Georges François Leclerc · Dijon, France
  • Centre Eugène Marquis · Rennes, France
Show 2 removed
  • Centre Georges François Leclerc · Dijon, France
  • Centre Eugène Marquis · Rennes, France
Nov 9, 2026
Start date
Jan 15, 2026→Mar 4, 2026 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    2 sites added, 2 sites removed. 9 sites changed recruiting status (6 now recruiting, 3 now not yet recruiting)
    Show 9 sites
    • Institut du Cancer de Montpellier · Montpellier, Franceno status→Recruiting
    • Institut de Cancérologie de l'Ouest · Saint-Herblain, Franceno status→Not yet recruiting
    • Centre Oscar Lambret · Lille, Franceno status→Recruiting
    • Centre de radiothérapie Bayard · Villeurbanne, Franceno status→Not yet recruiting
    • Centre Henri Becquerel · Rouen, Franceno status→Recruiting
    • Institut Sainte Catherine · Avignon, Franceno status→Recruiting
    • Centre de radiothérapie Saint-Louis · Toulon, Franceno status→Recruiting
    • Hôpital Tenon · Paris, Franceno status→Recruiting
    • Institut Curie · Saint-Cloud, Franceno status→Not yet recruiting
    Show 2 added (2 France)
    • Centre Georges François Leclerc · Dijon, France
    • Centre Eugène Marquis · Rennes, France
    Show 2 removed
    • Centre Georges François Leclerc · Dijon, France
    • Centre Eugène Marquis · Rennes, France
    Start date Jan 15, 2026→Mar 4, 2026 (now actual)
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07043543
Collaborators
Ligue contre le cancer, France
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Mar 4, 2026
Primary completion
Jan 30, 2029 (estimated)
Completion
Sep 30, 2033 (estimated)
Last update
Nov 9, 2026

Study contacts

Aurore MOUSSION
Contact
aurore.moussion@icm.unicancer.fr
467613102 ext. +33
Olivier RIOU, MD
principal investigator · INSTITUT REGIONAL DU CANCER DE MONTPELLIER

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion